trending Market Intelligence /marketintelligence/en/news-insights/trending/lOp6EHMzz7R1xeweKSNkIQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Report: China's I-Mab Biopharma files for $200M US IPO

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Report: China's I-Mab Biopharma files for $200M US IPO

Shanghai-based I-Mab Biopharma confidentially filed for a U.S. IPO that could raise about $200 million, Bloomberg News reported, citing people with knowledge of the matter.

The Chinese drugmaker is looking to raise up to $40 million in its latest private funding round, valuing the company at about $800 million, one of the sources added. WuXi Biologics (Cayman) Inc. and Hong Kong's billionaire Cheng family are reportedly among the investors participating in the funding round.

I-Mab, which develops therapies for cancer and autoimmune illnesses, is backed by Hillhouse Capital, private equity firm Ally Bridge Group, Hony Capital (Beijing) Co. Ltd. and CDH Investments, among others.

A Bloomberg report in August 2018 said the company was planning to raise up to $500 million in a Hong Kong IPO.